Related Experiment Video
Updated: May 11, 2026
07:48
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Targeting cell cycle and hormone receptor pathways in cancer
C E S Comstock1, M A Augello, J F Goodwin
1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Oncogene
|May 28, 2013
Summary
Selective CDK4/6 inhibition with PD-0332991 halts prostate cancer cell proliferation by inducing G1-arrest. This approach shows promise as a therapeutic target, especially when combined with other treatments, with retinoblastoma status predicting efficacy.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis regulates cell cycle entry and is frequently altered in human cancers.
- Novel therapeutic strategies are needed to prevent or treat malignancies.
Purpose of the Study:
- To investigate the antitumor properties and mechanisms of PD-0332991 (PD), a selective CDK4/6 inhibitor, in human prostate cancer (PCa) models.
- To evaluate PD's efficacy as a single agent and in combination therapies.
Main Methods:
- Utilized human prostate cancer cell lines, xenografts, and primary tumor explants.
- Assessed cell proliferation, cell cycle progression (G1-arrest), and modulation of key cell cycle regulators.
- Investigated combinations with hormone-based regimens and ionizing radiation.
Main Results:
- PD significantly inhibited PCa cell proliferation by inducing G1-arrest and modulating G1 cyclins.
- PD demonstrated anti-proliferative effects in PCa xenografts and primary tumor explants.
- PD showed potential to enhance hormone-based therapies and cooperate with ionizing radiation.
Conclusions:
- Selective CDK4/6 inhibition via PD hinders critical proliferative pathways in prostate cancer.
- RB status is a key prognostic factor for therapeutic response to PD.
- Targeting CDK4/6 represents a viable therapeutic strategy for early and advanced PCa, supporting personalized medicine.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...